Medical World News® After Hours: Oncologist Amy Comander, MD, Discusses Marathon Running and Motivation

Video

During an After Hours segment of Medical World News®, Amy Comander, MD, spoke about her passion for marathon running and how it helps keep her inspired in her work as an oncologist.

A recent ‘Narratives in Oncology’ article written for The Oncologist journal details the experience of physician and marathon runner Amy Comander, MD, with the 124th Boston Marathon. Like most events scheduled in 2020, the marathon was canceled due to the COVID-19 pandemic. In her narrative, Comander discusses gratitude and resilience in times of uncertainty, explaining how the running community has helped her remember to keep her head up.

In addition, Comander has helped organize fundraising races, like the PAVING Program 5K, a virtual 5k to be held June 4 through 6, 2021.

CancerNetwork® sat down with Comander, of the Mass General Cancer Center in Waltham and Harvard Medical School, to talk about what marathon running means to her and her plans for participating in future races.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

References

1. Comander A. Remember Your Why: An Oncologist's Reflections on Running During the COVID-19 Pandemic. Oncologist. 2021;26(4):348-349. doi:10.1002/onco.13683

Recent Videos
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.
Ronald Bleday, MD, credits a chronic pain clinic for consulting patients who may be at a greater risk for prolonged opioid use following surgery.
Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
A new START center in New York may give patients with advanced malignancies an opportunity to access novel therapies in the community setting.
START is the largest early phase oncology network in the community-based setting, according to Geraldine O’Sullivan Coyne, MD, MRCPI, PhD.
Related Content
Pioneer of Supportive Care Highlights Additional Needs in The Space

Pioneer of Supportive Care Highlights Additional Needs in The Space

Ariana Pelosci
August 27th 2025
Article

Declan Walsh, MD, highlighted how the supportive and palliative care space has evolved since he first began working in the field.

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

START Center Aims to Bring New Cancer Treatments, Trials to The Community

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
August 25th 2025
Podcast

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

Perceptions of Dermatologic AEs Could Impact Treatment Adherence

Perceptions of Dermatologic AEs Could Impact Treatment Adherence

Ariana Pelosci
August 21st 2025
Article

A survey found that patients believed dermatologic AEs were more prevalent with anti-cancer therapies than what has been reported.

Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.

An update of phase 1 data from the CTMX-2051-101 study is expected to be available by the first quarter of 2026.

Safety Review Committee Supports CX-2051 Trial Continuation in Solid Tumors

Roman Fabbricatore
August 15th 2025
Article

An update of phase 1 data from the CTMX-2051-101 study is expected to be available by the first quarter of 2026.

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Viviana Cortiana, MS4;Maduri Balasubramanian, MD;Jade Gambill, BS;Diksha Mahendru, MD;Kennedy Itodo, MD;Chandler H. Park, MD, MS, FACP;Yan Leyfman, MD
August 15th 2025
Article

Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.